Glycaemic targets in diabetesFwhat are they and why?
Landmark studies such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) show unequivocally that reducing hyperglycaemia reduces both the incident risk and progression of diabetic complications, with no threshold level of HbA 1c beneath which further prognostic advantage cannot be achieved. 1, 2 Data from the UKPDS, for example, suggest that for every reduction in glycated haemoglobin by 1% Hb there will be a 21% reduction in diabetes-related death, a 14% reduction in incidence of myocardial infarction, a 37% reduction in microvascular complications and a 43% reduction in peripheral vascular disease. 3 Recent guidelines issued by authorities such as the ADA and IDF, recommend target HbA 1c levels in the range 6.5-7% and fasting/preprandial glucose targets in the range 4.4-6.7 mmol/l. 4, 5 Evidence of glycaemic target achievement in clinical trials However, such levels of control are difficult to achieve in the majority of patients with type I and type II diabetesFeven within the confines of clinical trials. In type I patients in the DCCT the proportion of patients in the intensive intervention group that registered a target HbA 1c value (r6.05%) even once was just 44%, and only 5% maintained this goal throughout the study. 6 This was despite patients reportedly remaining on their assigned insulin regimens over 97% of the time. 7 In Europe, even with the support of the welldescribed structured and teaching training programme (STTP), involving 5 days of self-management training the mean HbA 1c remined above the target range. 8 Failure to achieve glycaemic targets was also well illustrated in the Steno-2 study, in which patients with type II diabetes were randomised to conventional or intensive treatment groups targeting a series of cardiovascular risk factors as well as optimising glycaemic control. 9 In the intensively managed cohort, 50-80% of patients achieved guideline targets for lipids and blood pressure, yet fewer than 20% achieved the HbA 1c target of 6.5%.
The clinical reality: glycaemic control in 'real life'
Data concerning the levels of glycaemic control achieved in populations with diabetes in the general clinical setting are not encouraging. In the UK a large dataset of over 600 000 from across the country in the year 2000 reported a mean It is therefore of health and economic importance to identify the causes of continuing suboptimal glycaemic control in patients with diabetes requiring insulin therapy. There are a number of issues that are fundamental to optimisation of glycaemic control. These include the pathophysiology of the disease itself, provision of healthcare by physicians and associated healthcare professionals, structured education and self-management skills of patients, and optimal insulin therapy. In this article each of these areas is considered and potential barriers and shortcomings identified.
Aspects of pathophysiology of the disease and its therapy
Disease progression A major problem in the achievement of glycaemic targets in type II diabetes is that the disease is progressive. Thus, interventions that initially achieve glycaemic targets are likely to be inadequate within a few years. This was well illustrated in UKPDS where median HbA 1c reached the upper limit of normal at 6.2% a year after randomisation with intensive therapy, but then progressively worsened to 8% over the next 8 years. 2 This decline in control was associated with progressive loss of beta-cell function, and backward extrapolation of data describing beta-cell function from time of diagnosis suggested that patients were not diagnosed with diabetes until an average of 12 years from the commencement of the disease process. 19 In the setting of a changing pathophysiological background, it is unsurprising that interventions fail to recover and then sustain euglycaemia. Even insulin therapy will need to be intensified to compensate for disease progression. All type I and many type II patients will require exogenous insulin therapy and are therefore at risk of the side effects such as hypoglycaemia and weight gain. Such problems are associated with most of the currently available exogenous insulin regimens that continue to have substantial pharmacological limitations.
Hypoglycaemia
Hypoglycaemia continues to be a problem for both type I and type II patients on insulin therapy. In type I patients in the DCCT, the risk of hypoglycaemia was inversely related to the glycaemic control achieved. However, patients in the intensively treated group had a consistently higher risk of hypoglycaemia than those in the conventional group at all levels of HbA 1c , indicating that the intensive insulin regimen per se contributed to the risk. Patients and their relatives cite hypoglycaemia (particularly nocturnal episodes) among their greatest fears. 20, 21 Ultimately, a patient's tolerance of hypoglycaemic risk defines the glycaemic target that can practically be aimed for and has a major influence on treatment decision making. 22, 23 Rates of hypoglycaemia are often quoted in a clinical trial setting, and often in patients with either a short duration of the disease or those who have had insulin therapy for a short time. This may lead to rates being underestimated. In the UKPDS rates of 37 per 100 patient years for any hypoglycaemia and 2.3 per 100 patient years for severe episodes were reported. 2 This is an order of magnitude less than that seen in the DCCT in type I patients. However, in studies of type II patients where the duration of insulin therapy was matched with type I patients the prevalence of hypoglycaemia seen in type II patients approached that of type I patients. 24 A recent study using continuous blood glucose monitoring in type II patients on premixed insulin regimens reported rates of nocturnal hypoglycaemia of around 8%. 25 Whether rates of hypoglycaemia in type II patients would be different using alternative approaches to insulin therapy requires further investigation.
Weight gain
In type I patients in the DCCT, the mean weight of intensively treated patients increased to levels beyond the ideal, with a significant proportion of patients, especially women, increasing their body mass index by at least 5 kg/m 2 . 26, 27 Weight gain in DCCT was also associated with adverse changes in cardiovascular risk profile, 28 and was significantly greater in patients who experienced severe hypoglycaemia 26 suggesting a linkFperhaps compensatory overeating.
Weight gain in type II diabetes is an important issue. Many patients are already overweight with a significant proportion obese. Many have co-morbidities that are adversely affected by weight gain. In the intensive arm of the UKPDS weight gain in the region of 5 kg was seen. 2 When optimising glycaemic control in type II diabetes, choice of an insulin regimen, that limits potential weight gain is an important factor.
Healthcare professional factors in suboptimal glycaemic control
Delayed initiation of insulin Concerns about causing hypoglycaemic episodes or increasing patients' obesity means that physicians may permit poor control to continue unduly by delaying the initiation or intensification of insulin therapy. The problem may also be compounded by their doubts about patients' ability to cope with insulin injections. All too frequently, carers regard insulin as treatment of last resort. The extent of care-givers' reticence to use insulin has been well illustrated by the Diabetes Attitudes Wishes and Needs (DAWN) study, the largest global psychosocial diabetes survey undertaken. 29 Interviews were conducted with over 5000 people with diabetes and about 4000 healthcare professionals in 13 countries. Significant among the findings presented are that 59% of general practitioners, 42% of diabetes specialist physicians and 51% of diabetes specialist nurses agreed with the statement that 'I prefer to delay initiation of insulin until absolutely essential'. Only about 50% of care-givers agreed with the statement that 'Earlier introduction of insulin would decrease the overall cost of diabetes care in the long term'. Thus, although it is well accepted that improved control benefits prognosis, perhaps this knowledge is not always extrapolated to treatment decisions made at the level of individual patients. Some 60% of care-givers believed their patients would be 'Very worried about having to start on insulin', while some 30-40% considered their patients would agree that 'Starting insulin would mean that I have not followed my treatment recommendations properly'. This implies that the initiation of insulin may be regarded as an indication of failure and, anecdotally, is still used by some healthcare professionals as a threat.
Evidence that initiation of insulin is inappropriately delayed in type II patients is confirmed by the levels of glycaemic control at the point at which patients with type II diabetes are commenced on insulin in longitudinal surveys (Figure 1 ). In such publications, the decision to start insulin is not determined by study protocols but reflects decision making by healthcare professionals; typically, HbA 1c has been above 9% on initiation of insulin. [30] [31] [32] [33] [34] Of interest, is the observation that there has been no improvement between the earliest and most recently published surveys in terms of the point of the level of HbA 1c at which insulin is initiated ( Figure 1 ).
Delayed intensification of insulin
In patients with type I diabetes already on insulin, healthcare professionals may be slow to intensify its use. Again, there is a paucity of data in the literature concerning the levels of glycaemic control at which insulin therapy is typically intensified, intensification being defined as a move to multiple injection regimens (often a basal-bolus regimen) with short-acting and isophane insulin. Increasingly shortacting and basal insulin analogues are being used for this purpose. However, clues are provided in a review of early prospective studies of multiple injection therapy investigating control in (predominantly) type I patients, where cohorts were monitored before and following intensification ( Figure 2 ). 35 Here, the mean HbA 1c values in cohorts chosen for intensification were high. All studies showed that overall glycaemic control improved following insulin intensification, implying a patient benefit that had previously been missed, but HbA 1c remained suboptimal in most cases. It must be remembered, however, that these studies predated the introduction of rapid-acting analogues. Undue delay in intensification of insulin is especially unacceptable in light of data from the EDIC study in which subjects from the DCCT cohort were followed up after completion of the original randomised trial. 36 This study showed that after completion of DCCT, the HbA 1c values of the intensively and conventionally treated cohorts converged as treatment of the latter group tended to intensify. But despite this 'catch-up' in glycaemic control, the relative prognostic advantages achieved by the intensively treated patients in DCCT were preserved years after the trial was completed. Thus, the potential harm of hyperglycaemia appears to be cumulative and irreversible. Clearly, healthcare professionals should strive to reduce patients' blood glucose levels to the lowest levels possible, and do this as early as possible.
In type II diabetes the choice of insulin regimen, and issue of intensification of therapy is much more controversial. There is continued debate as to the best approach for insulin imitation in type II diabetes, some favour basal, others prandial and more commonly a premixed insulin approach is used. Furthermore, there is a whole raft of oral hyperglycaemic agents that can be used in combination with insulin, including metformin and sulphonylureas. The choice is vast, the data in this area are often confusing and the need for clarity and guidance is urgent. There is a lack of robust evidence as to the relative advantages and disadvantages of different insulin regimes in type II diabetes and the recently announced 4T study (treating to target type II diabetes), which will study this specific area, is to be welcomed.
Patient education and support
An interesting observation in the DAWN study concerned the time afforded to patients in consultations. The average diabetes consultation with a general practitioner lasted 10 min while consultations with diabetes specialist physicians and nurses respectively averaged 13 and 20 min. A desire for more time to be available for diabetes consultations was expressed by 64% of general practitioners, 69% of specialist physicians and 57% of specialist nurses. This finding implies a belief that there is scope for improving the self-management skills of patients given sufficient time. Indeed, patients' self-management skills and clinical course do improve greatly in response to structured education. For example, an Austrian study evaluated the impact of a 5-day Mohrle et al. 38 
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Patient factors contributing to suboptimal glycaemic control
Patient concerns in diabetes
The concerns of patients and the issues that impede their success in self-management are well documented. For example, in a survey of 164 students with type I diabetes in the USA, the most commonly reported barriers to effective glycaemic control included diet, irregular schedules, lack of parental involvement, peer pressure, drugs and alcohol, fear of hypoglycaemia, and finances. 45 Factors associated with improved control were an increased sense of responsibility, increased frequency of blood glucose testing, exercise, contact with healthcare providers, fear of hyperglycaemia, and knowledge of the results of the DCCT. Thus, the knowledge and understanding imparted by good education from care-givers was again associated with real clinical benefit. In type II diabetes, where insulin therapy is generally not an inevitability at the time of diagnosis, needle phobia presents as a common additional barrier to good control.
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The DAWN study has demonstrated the extent to which anxiety and stress are present in people with diabetes. Approximately half those questioned with type I diabetes feared their disease becoming worse, but an equal proportion was 'very worried' about their risk of hypoglycaemic events, with 40% 'very anxious' about their weight. Among people with type II diabetes, the respective proportions were 43% (disease progression), 39% (hypoglycaemia) and 55% (weight). These findings mirrored an earlier survey of 411 patients with type I diabetes that showed the level of patient concern about severe hypoglycaemia to be equal to that regarding the threat of blindness and to exceed that regarding the threat of renal complications. 47 When concerns about short term insulinassociated side effects are as frequent as concerns about prognosis, it is not surprising that some patients do not fully grasp the need to strive for tight glycaemic targets, which may in turn lead to long-term health benefits.
Adherence to insulin and self-management tasks Several studies have formally investigated patient adherence and diabetes self-management and while results have differed somewhat, all suggest scope for improvement, particularly with regard to self-monitoring, diet and exercise. For example, in a survey of 289 adolescent patients in Finland, only 25% reported full compliance with dietary and self-monitoring advice, with 51% admitting poor compliance to self-monitoring. 48 On the other hand, 81% claimed full adherence to their insulin regimens. In this study, patients' overall perception of compliance with treatment advice was a clear predictor of glycaemic control (Figure 3 ). These data also reveal the small proportion of patients with good glycaemic control. Similar findings have been repeated elsewhere. In the DAWN study, the percentage of patients with type I diabetes reporting good adherence to insulin therapy was 83%, with 70, 39 and 38% reporting good adherence to self-monitoring, diet and exercise advice, respectively. In a survey of 93 insulin-treated patients in the USA, 92% claimed never to miss an insulin injection, 98% claimed 'full mean adherence' to insulin and 77% claimed that they always injected within 30 min of recommended times. 10 In contrast, 70% claimed adherence to self-monitoring advice and only 58% claimed adherence to dietary advice. In this study, there was no obvious correlation between adherence and glycaemic control suggesting other factors may determine the outcome. That poor adherence to self-monitoring may have a considerable clinical impact was highlighted in a recent survey of 40 patients with type II diabetes. 49 This showed that glucose monitoring can heighten patients' awareness of the impact of their lifestyle. However, glucose monitoring While the data from self-report studies indicate that adherence to insulin therapy, if not other aspects of selfcare, is actually quite good, this has not been confirmed in objective studies of adherence. In a UK study of 89 young insulin-treated patients attending a hospital diabetes clinic over a 2-y period, an attempt was made to gauge adherence by assessing redemption of insulin prescriptions initiated by the hospital. 50 Here, the mean adherence index (maximum possible insulin coverage based on dispensed doses relative to prescribed doses) was 486 days. This apparent 'overdispensation' might suggest good compliance, but largely reflects the unit sizes of insulin products. In fact, 28% of patients collected less than 365 days' worth of insulin (mean 250), so the proportion of poorly adherent patients must have been substantially higher than this. Poor adherence was most noticeable in adolescents, where it was associated with the poorest control ( Figure 4 ). It is, however, possible that this study is unrepresentative by selecting particularly poorly adherent subjects; many were originally admitted to hospital with ketoacidosis or diabetic complications. Nevertheless, poor patient adherence as a potential primary cause of poor control was clearly demonstrated.
The burden of polypharmacy Furthermore, adherence to prescribed treatment regimens may still be compromised by the number and complexity of tasks involved. Many patients with diabetes will be taking polypharmacy for co-morbidities and such treatment regimens may be especially burdensome for elderly patients with type II diabetes where it is not uncommon for a raft of cardiovascular risk modulating drugs to be prescribed. 51 In one recent survey of 128 patients with type II diabetes, the mean number of diabetes-related medicines taken was 4.171.9. 52 However, the total number of medicines prescribed was not correlated with adherence in this study, although unreported side effects and patients' lack of confidence in treatment benefits were common causes of suboptimal adherence to individual medications. Number of patients Figure 3 Patient perception of overall adherence to treatment recommendations as a predictor of glycaemic control. Data from Kyngas.
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The contribution of insulin to suboptimal glycaemic control in diabetes
If insulin were to be initiated and intensified promptly, and patients had access to effective structured education which supported them to self-manage, it would still be unrealistic to expect achievement of euglycaemia, as evidenced by the low rates of target achievement in target-driven clinical trials. 7, 9 It follows that even the most sophisticated modern intensive insulin regimens must be failing to re-create optimal dynamic insulinaemic profiles on a day-by-day basis. Indeed, were insulin regimens able to achieve this, then many of the insulin 'issues' discussed above would be redundant.
The inherent limitations of insulin administered by the subcutaneous route
The exogenous administration of insulin is inevitably unphysiological and problematic. 53 When insulin is injected or infused subcutaneously it is absorbed into the peripheral venous system and circulated systemically, whereas in normal physiology insulin is secreted into the portal vein, acting firstly on the liver where extensive extraction occurs. It is therefore likely that the nutrient regulatory potential of exogenously administered insulin is inherently compromised. Furthermore, the absorption of subcutaneous insulin is a variable and unpredictable process such that plasma insulin levels may depart from those intended. [54] [55] [56] [57] This is likely to be a particular problem with long-acting insulin formulations that are either injected as preformed suspensions or which precipitate following injection. 57, 58 This is partly because the process of insulin dissolution is unpredictable, and partly because a prolonged depot residence time increases the opportunity for local factors affecting absorption, such as depot blood flow rate, to vary.
Basal-bolus therapyFthe gaps between theory and clinical deployment
Most patients with type I diabetes and increasing numbers of type II patients who are being treated with intensified insulin therapy receive a 'basal-bolus' regimen, which attempts to mimic the healthy physiological insulin profile. The theory is that a rapidly absorbed insulin preparation (taken before meals) will have a fast onset and short duration of action and thereby mimic the prandial insulin response, while a longer-acting preparation with protracted absorption will substitute the basal insulin output of normal physiology. The mean pharmacokinetic profiles of commercially available insulin preparations can, in theory, be combined to create dynamic insulinaemic profiles that approximate normal physiology, but the clinical reality is that these exact mean profiles are seldom reproduced. In fact, variability around the mean profile can be considerable with basal insulin preparations, giving rise to substantially different pharmacodynamic profiles from one injection to another.
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The clinical manifestation of this effect following the evening injection of basal insulin is that patients may experience nocturnal hypoglycaemia if absorption proceeds atypically quickly, and they can wake to fasting hyperglycaemia if absorption is atypically fast or slow. A further irony is the increasing clinical use of mealtime rapid-acting insulin analogues in place of soluble human insulin. While analogues improve postprandial glycaemic control, the switch to these agents often obliges an increase in the basal insulin dose ( Figure 5 ). However, the extent to which this can be done is limited by the fact that patients then face greater exposure to the pharmacokinetic limitations of the basal component of their regimen. 58, 59, 61 Thus, while postprandial glycaemic control might benefit, improvements in HbA 1c levels have often been modest comparing rapid-acting analogues with human insulin-based regimens. It is clear that further improvements must be sought in basal insulin preparations, with a reduction in absorption variability being a key requirement.
Conclusion
In summary, despite universal acceptance of its clinical benefits, good glycaemic control remains uncommon, even in insulin-treated diabetes. The reasons for this are complex and multifactorial. In addition to the progressive pathophysiology of type II diabetes inadequacies are all too easily found at the level of healthcare provision, patient selfmanagement and access to effective structured education, and insulin treatment itself. Physicians are often too slow to initiate insulin and too reluctant to intensify its use. Healthcare professionals would ideally spend more time educating patients, but time and access to well evaluated structured education programmes that facilitate patient selfmanagement are lacking. For their part, patients are also Glycaemic control in insulin treated diabetes M Davies often reluctant to begin or intensify insulin, and evidence suggests that they can be struggling with many aspects of self-management if not in the use of insulin itself. Finally, there is, in any case, a limit to what can be achieved with current insulin therapies and this may underpin the behavioural issues. Inappropriate and variable pharmacological time-action profiles mean that today's regimens do not routinely deliver the effects we may assume of them.
Variability may lie at the heart of many of the current limitations of exogenous insulin therapy such as its propensity for causing hypoglycaemia and weight gain. An improvement in the overall level of glycaemic control in diabetes mellitus is most likely to be seen if healthcare professionals and patients are able to change some attitudes about insulin use, and the onus is firmly upon healthcare providers to better equip patients in this respect. It is clear that the insulin products available are not currently being used to maximum effect, but it is equally clear that further refinements of insulin preparations are needed. In type II diabetes in particular, more robust data are needed as to the most effective approach to insulin management.
